The Future of Precision Oncology

We provide innovative protein technology for pancreatic cancer

About

Reccan Diagnostics is a company based on research performed at Lund University. We have developed a biotechnology platform for in vitro diagnostics, providing both earlier and more specific diagnosis, as well as improved prognostic stratification of solid cancers. The technology platform is based on a patented combination of unique protein biomarkers detectable in blood and cancer tissue samples. The primary focus area is pancreatic cancer, currently the third leading cause of cancer-related death. Pancreatic cancer is projected to become the second cause of cancer death within a few years if no action is taken.

Pancreatic cancer is a disease where early detection substantially improves the prognosis for the patient. A diagnostic test for pancreatic cancer should be simple, accurate and non-invasive.

 

CONTACT US

Roland Andersson, CEO

+46 (0)706-63 23 46

info@reccandiagnostics.com

 

Reccan Diagnostics AB

Org no. 556985-4192